|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
52,373,000 |
Market
Cap: |
2.52(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$30.85 - $52.9 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 474 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vericel is a biopharmaceutical company providing cell therapies for the sports medicine and severe burn care markets. Co.'s products include: MACI®, which is an autologous cellularized scaffold product indicated for the repair of symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults; and Epicel®, which is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Co. also holds a license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
134,738 |
259,234 |
263,234 |
303,833 |
Total Sell Value |
$6,189,261 |
$10,761,080 |
$10,907,920 |
$12,010,179 |
Total People Sold |
5 |
7 |
7 |
7 |
Total Sell Transactions |
12 |
29 |
31 |
34 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hopper Jonathan Mark |
Chief Medical Officer |
|
2022-02-06 |
4 |
D |
$33.91 |
$10,512 |
D/D |
(310) |
44,044 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2022-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
650 |
44,354 |
|
- |
|
Mara Joseph Anthony Jr |
Chief Financial Officer |
|
2021-12-31 |
4 |
D |
$39.30 |
$46,138 |
D/D |
(1,174) |
11,613 |
|
- |
|
Mara Joseph Anthony Jr |
Chief Financial Officer |
|
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
12,787 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2021-12-22 |
4 |
AS |
$40.08 |
$596,930 |
D/D |
(14,881) |
43,547 |
|
-23% |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2021-12-22 |
4 |
OE |
$10.95 |
$265,150 |
D/D |
19,000 |
49,428 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2021-12-20 |
4 |
AS |
$40.00 |
$40,000 |
D/D |
(1,000) |
39,428 |
|
-25% |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2021-12-20 |
4 |
OE |
$10.95 |
$10,950 |
D/D |
1,000 |
40,428 |
|
- |
|
Gilman Steven C |
|
|
2021-10-27 |
4 |
AS |
$50.57 |
$252,870 |
D/D |
(5,000) |
3,500 |
|
-28% |
|
Gilman Steven C |
|
|
2021-10-27 |
4 |
OE |
$3.74 |
$18,700 |
D/D |
5,000 |
8,500 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2021-10-26 |
4 |
AS |
$50.57 |
$505,689 |
D/D |
(10,000) |
5,696 |
|
-26% |
|
Halpin Michael |
Chief Operating Officer |
|
2021-10-26 |
4 |
OE |
$2.65 |
$26,500 |
D/D |
10,000 |
15,696 |
|
- |
|
Gilman Steven C |
|
|
2021-09-30 |
4 |
AS |
$48.85 |
$244,255 |
D/D |
(5,000) |
3,500 |
|
-27% |
|
Gilman Steven C |
|
|
2021-09-30 |
4 |
OE |
$3.74 |
$18,700 |
D/D |
5,000 |
8,500 |
|
- |
|
Mara Joseph Anthony Jr |
Chief Financial Officer |
|
2021-09-30 |
4 |
D |
$48.80 |
$57,291 |
D/D |
(1,174) |
8,720 |
|
- |
|
Mara Joseph Anthony Jr |
Chief Financial Officer |
|
2021-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
9,894 |
|
- |
|
Flynn Sean C. |
VP, General Counsel |
|
2021-08-27 |
4 |
AS |
$55.11 |
$396,760 |
D/D |
(7,200) |
2,419 |
|
-34% |
|
Flynn Sean C. |
VP, General Counsel |
|
2021-08-27 |
4 |
OE |
$16.25 |
$117,000 |
D/D |
7,200 |
9,619 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2021-08-16 |
4 |
AS |
$48.03 |
$720,480 |
D/D |
(15,000) |
5,623 |
|
-14% |
|
Halpin Michael |
Chief Operating Officer |
|
2021-08-16 |
4 |
OE |
$2.65 |
$39,750 |
D/D |
15,000 |
20,623 |
|
- |
|
Flynn Sean C. |
VP, General Counsel |
|
2021-07-21 |
4 |
AS |
$55.01 |
$154,028 |
D/D |
(2,800) |
2,419 |
|
-30% |
|
Flynn Sean C. |
VP, General Counsel |
|
2021-07-21 |
4 |
OE |
$16.25 |
$45,500 |
D/D |
2,800 |
5,219 |
|
- |
|
Flynn Sean C. |
VP, General Counsel |
|
2021-07-15 |
4 |
AS |
$51.18 |
$511,786 |
D/D |
(10,000) |
2,419 |
|
-15% |
|
Flynn Sean C. |
VP, General Counsel |
|
2021-07-15 |
4 |
OE |
$16.25 |
$162,500 |
D/D |
10,000 |
12,419 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2021-07-12 |
4 |
AS |
$53.54 |
$1,070,876 |
D/D |
(20,000) |
5,623 |
|
-24% |
|
303 Records found
|
|
Page 7 of 13 |
|
|